zum Inhalt springen
Simonis, A., Kreer. C., Albus, A., Rox, K., Yuan, B., ...., Theobald, S.J., Hellmann, A.M., Meyer, C., Ercanoglu, M.S., ..., Hallek, M., Fätkenheuer, G., Koch, M., ..., Klein, F., and Rybniker, J.

Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa

Abstract

Drug-resistant Pseudomonas aeruginosa (PA) poses an emerging threat to human health with urgent need for alternative therapeutic approaches. Here, we deciphered the B cell and antibody response to the virulence-associated type III secretion system (T3SS) in a cohort of patients chronically infected with PA. Single-cell analytics revealed a diverse B cell receptor repertoire directed against the T3SS needle-tip protein PcrV, enabling the production of monoclonal antibodies (mAbs) abrogating T3SS-mediated cytotoxicity. Mechanistic studies involving cryoelectron microscopy identified a surface-exposed C-terminal PcrV epitope as the target of highly neutralizing mAbs with broad activity against drug-resistant PA isolates. These anti-PcrV mAbs were as effective as treatment with conventional antibiotics in vivo. Our study reveals that chronically infected patients represent a source of neutralizing antibodies, which can be exploited as therapeutics against PA.

Read more at Cell. 186, 5098-5113